Vol. 27.Issue. 2. March - April 2022 | Annals of Hepatology

Tienda Elsevier

¿Aún no está registrado?

Información relevante

Consulte los artículos y contenidos publicados en éste medio, además de los e-sumarios de las revistas científicas en el mismo momento de publicación

Máxima actualización

Esté informado en todo momento gracias a las alertas y novedades

Promociones exclusivas

Acceda a promociones exclusivas en suscripciones, lanzamientos y cursos acreditados

Crear Mi cuenta

* = Required fields

Enter your email address

User name *

Annals of Hepatology

Annals of Hepatology

Annals of Hepatology

ISSN: 1665-2681

Annals of Hepatology (AoH) is an international, open access journal published bi-monthly with funds from the Fundación Clínica Médica Sur. It is the official journal of the Mexican Association of Hepatology (AMH), the Latin American Association for the Study of the Liver (ALEH), the Canadian Association for the Study of the Liver (CASL) and the Czech Society of Hepatology (CSH). AoH publishes editorials, opinions, concise reviews, original articles, brief reports, letters to the editor, news from affiliated associations, clinical practice guidelines and summaries of congresses in the field of Hepatology.

Topics covered by AoH include alcoholic liver disease, autoimmune hepatitis, biliary diseases, drug-induced liver injury, genetic liver diseases, NAFLD/NASH and viral hepatitis (HAV, HBV, HCV, HDV, HEV). Our journal seeks to publish articles on basic clinical care and translational research focused on preventing rather than treating the complications of end-stage liver disease.

See more Open Access Option

Indexed in:

Scopus, Medline, Directory of Open Access Journals (DOAJ), Science Citation Index Expanded (SCIE), SCImago Journal Rank (SJR), SNIP

See more

Follow us:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2025

See more

Impact factor 2024

4.4

Citescore

CiteScore measures average citations received per document published.

See more

Citescore 2024

9.1

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

See more

SJR 2024

1.011

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

See more

SNIP 2024

1.057

View more metrics

Journal Information

Previous Issue | Next Issue

Issue

portada-S1665268121X00117

Vol. 27. Issue 2.

(March - April 2022)

EDITORIAL BOARD

Ann Hepatol. 2022;27:100694

Full text access

Share

Editorial

Training in Hepatology: From medical school to a Ph.D. and clinical specialty program

Arturo Panduro

Ann Hepatol. 2022;27:100682

Full text access

Share

Concise reviews

Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing

Fan Yang, Kaige Deng, Haoran Zheng, Zhenting Liu, Yongchang Zheng

Ann Hepatol. 2022;27:100677

Full text access

Share

Acid-base abnormalities and liver dysfunction

Periklis Katopodis, Efthymios M. Pappas, Konstantinos P. Katopodis

Ann Hepatol. 2022;27:100675

Full text access

Share

Original articles

Introduction of a standardized protocol for cardiac risk assessment in candidates for liver transplant – A retrospective cohort analysis

Killian J. McCarthy, Daniel Motta-Calderon, Alisson Estrada-Roman, Karen M. Cajiao, Michael P. Curry, Alan Bonder, Anne-Marie Anagnostopoulos, Michael Gavin

Ann Hepatol. 2022;27:100582

Full text access

Share

Silencing lncRNA NEAT1 reduces nonalcoholic fatty liver fat deposition by regulating the miR-139-5p/c-Jun/SREBP-1c pathway

Si-Si Jin, Chun-Jing Lin, Xian-Fan Lin, Ju-Zeng Zheng, Hua-Qin Guan

Ann Hepatol. 2022;27:100584

Full text access

Share

Laparoscopic cholecystectomy: Histopathological analysis of metabolic associated fatty liver disease and fibrosis

Itzayana Rodríguez-Antonio, Guillermo N. López-Sánchez, Víctor A. Reyes-Gómez, Ericka H. Contreras-Flores, Fernanda Farías-García, Mariana Espejel-Deloiza, Marco A. Durán-Padilla, Fredy Chablé-Montero, ... Natalia Nuño-Lámbarri

Ann Hepatol. 2022;27:100651

Full text access

Share

Long-term prediction of hepatocellular carcinoma using serum autotaxin levels after antiviral therapy for hepatitis C

Wataru Ando, Fumihiko Kaneko, Satoshi Shimamoto, Koji Igarashi, Katsuya Otori, Hiroaki Yokomori

Ann Hepatol. 2022;27:100660

Full text access

Share

Prevalence of fatty liver disease after liver transplantation and risk factors for recipients and donors

Kentaro Horiuchi, Tomomi Kogiso, Takaomi Sagawa, Makiko Taniai, Yoshito Kotera, Hiroto Egawa, Katsutoshi Tokushige

Ann Hepatol. 2022;27:100670

Full text access

Share

Ubiquitin-specific protease 1 acts as an oncogene and promotes lenvatinib efficacy in hepatocellular carcinoma by stabilizing c-kit

Zhangbin Chen, Yifei Ma, Zhitang Guo, Dingyuan Song, Zili Chen, Min Sun

Ann Hepatol. 2022;27:100669

Full text access

Share

Nomogram for prediction of long-term survival with hepatocellular carcinoma based on NK cell counts

Lihua Yu, Xiaoli Liu, Xinhui Wang, Dongdong Zhou, Huiwen Yan, Yuqing Xie, Qing Pu, Ke Zhang, Zhiyun Yang

Ann Hepatol. 2022;27:100672

Full text access

Share

Caffeine mitigates experimental nonalcoholic steatohepatitis and the progression of thioacetamide-induced liver fibrosis by blocking the MAPK and TGF-β/Smad3 signaling pathways

Eduardo E. Vargas-Pozada, Erika Ramos-Tovar, Consuelo Acero-Hernández, Irina Cardoso-Lezama, Silvia Galindo-Gómez, Víctor Tsutsumi, Pablo Muriel

Ann Hepatol. 2022;27:100671

Full text access

Share

Circ-LARP1B knockdown restrains the tumorigenicity and enhances radiosensitivity by regulating miR-578/IGF1R axis in hepatocellular carcinoma

Shuangmei Zhu, Yong Chen, Hong Ye, Baoqiang Wang, Xiang Lan, Hanying Wang, Sijie Ding, Xiao He

Ann Hepatol. 2022;27:100678

Full text access

Share

Gut microbiota dysbiosis in patients with hepatitis B virus-related cirrhosis

Wu Shu, Chen Shanjian, Lin Jinpiao, Ou Qishui

Ann Hepatol. 2022;27:100676

Full text access

Share

Brief report

Economic evaluation of long-term albumin use in cirrhosis patients from the Mexican healthcare system perspective

Carlos Moctezuma-Velazquez, Graciela Castro-Narro, Pablo Simó, Elisabet Viayna, Susana Aceituno, Maria Soler, Aldo Torre

Ann Hepatol. 2022;27:100673

Full text access

Share

Letters to the editor

Liver transplant outcomes during the COVID-19 pandemic

Manuel Mendizabal, Josefina Pages, Federico Piñero, Marcos Thompson, Marcelo O Silva

Ann Hepatol. 2022;27:100656

Full text access

Share

The role of basiliximab in renal function after liver transplantation

Mikel Gastaca

Ann Hepatol. 2022;27:100661

Full text access

Share

Prevalence of non alcoholic fatty liver disease and associated factors?

Segundo Moran

Ann Hepatol. 2022;27:100659

Full text access

Share

Reply to: “correspondence about “Efficacy and safety of basiliximab”

Mohamed Hashim, Ayman Alsebaey, Amr Ragab, Hossam Eldeen Soliman, Imam Waked

Ann Hepatol. 2022;27:100679

Full text access

Share

Reply to letter to the editor

Edgar Denova-Gutiérrez

Ann Hepatol. 2022;27:100674

Full text access

Share